Earlier this month, a new cancer drug captivated patients and investors. Now the lawyers get their turn. On Monday, the biotech Erasca said it had

Members of Utah’s medical licensing board have called for the suspension of a temporary program allowing a startup to use AI to refill prescription medications.

Intellia Therapeutics reported this morning on the Phase 3 success of a gene editing treatment for hereditary angioedema, a disease that causes unpredictable, disfiguring and

Oruka Therapeutics’ Phase 2 psoriasis data could mean there’s a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients

Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.